Drug resistance remains the central unsolved problem in multiple myeloma, a blood cancer where most patients eventually relapse despite initial responses to modern therapies. Understanding precisely why resistance emerges — and which tumor cells drive it — has been one of oncology's most pressing questions. Single-cell multi-omics technologies are now providing answers at a resolution that bulk tumor sequencing simply cannot reach.
This review in Leukemia & Lymphoma synthesizes how single-cell approaches have mapped the architecture of myeloma drug resistance. Key findings center on the identification of pre-existing resistant subclones that survive initial treatment and subsequently expand, alongside non-genetic mechanisms — including epigenetic reprogramming and transcriptional plasticity — that allow tumor cells to shift identity without acquiring new mutations. Beyond the cancer cells themselves, single-cell analyses have characterized inflammatory stromal remodeling and immune exhaustion within the bone marrow microenvironment, revealing how the tumor's ecosystem actively cooperates in undermining therapy. The review also addresses a significant methodological vulnerability: analytical heterogeneity across laboratories generates reproducibility problems that can obscure genuine biological signals, and the authors propose computational best practices to address this.
This synthesis arrives at a genuinely important inflection point for precision oncology. Myeloma has historically been studied through bulk sequencing, which averages signals across millions of cells and masks the rare resistant populations that matter most clinically. Single-cell resolution changes that calculus entirely. The translational challenge now is converting high-resolution molecular portraits into actionable clinical tools — better prognostic models, rational drug combinations, and new therapeutic targets. The reproducibility concern raised here is not trivial; it reflects a field-wide issue where computational pipeline choices can dramatically alter biological conclusions. As a review rather than an original clinical trial, this work is synthesizing existing evidence rather than generating new data, so its value lies in establishing analytical standards and pointing toward mechanistic targets that warrant prospective validation. For the myeloma research community, it represents a timely consolidation of an rapidly maturing field.